EVFM · Evofem Biosciences, Inc.

Summary

Evofem Biosciences, Inc. and Windtree Therapeutics, Inc. entered into a Termination Agreement on March 13, 2026, mutually terminating their License and Supply Agreement (originally dated March 20, 2025, and amended) with no termination fees payable. Certain customary survival provisions of the original agreement remain in effect, and Windtree must cease using the company's IP and return confidential information.

Key takeaways

• Termination Agreement effective March 13, 2026, between Evofem Biosciences, Inc. and Windtree Therapeutics, Inc.
• Terminates License and Supply Agreement dated March 20, 2025 (amended March 28, 2025) for PHEXXI® manufacturing and supply
• No termination fees or other payments due to either party
• Windtree to immediately cease using Buyer Specifications, Assets, Confidential Information, and Intellectual Property
• Customary survival provisions from Section 11.6 of the original agreement remain in effect